NO950725L - Pressure transdermal drug delivery device - Google Patents
Pressure transdermal drug delivery deviceInfo
- Publication number
- NO950725L NO950725L NO950725A NO950725A NO950725L NO 950725 L NO950725 L NO 950725L NO 950725 A NO950725 A NO 950725A NO 950725 A NO950725 A NO 950725A NO 950725 L NO950725 L NO 950725L
- Authority
- NO
- Norway
- Prior art keywords
- drug
- hours
- patient
- layer
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Transdermal medlkament-avleverlngsinnretning (10) som kan bil båret av en menneskelig pasient i 24 timer, mens den kontinuerlig avleverer et medikament til pasienten tilnærmet 16 timer, blir fremstilt ved en spesiell fremstilllngsmetode. Innretningen (10) er særlig nyttig med hensyn på avlevering av medikamenter, som dersom de blir avlevert i 24 timer, resulterer l problemer slik som medlkamenttoleranse (for eksempel nitroglycerin) eller søvnforstyrrelser (for eksempel nikotin). Medikamentet blir ladd i innretningen (10) l en konsentrasjon slik at medikamentet blir uttømt fra innretningen etter tilnærmet 16 timer l en slik grad at avleverlngshastlgheten av medikament til pasienten synker l en slik grad at den farmakologiske effekten av medikamentet på pasienten hovedsakelig blir ikke- ekslsterende. Innretningen (10) er l form av en laminert komposltt som er tilpasset til å bil festet til et bestemt område av ubrutt hud eller mukosavev. De individuelle lagene av innretningen Innbefatter et øvre bak eller, "ytre hud" lag (11), et ankeradhesivt lag (12), et kildelag (13) i hvilket medikament og/eller bærere til å begynne med er avsatt, et kontaktadhesiv (14) som er tilpasset til å festes til hud eller mukosa, og et frlgjørlngslag (15).Transdermal drug delivery device (10) capable of being carried by a human patient for 24 hours while continuously delivering a drug to the patient for approximately 16 hours is prepared by a special method of preparation. The device (10) is particularly useful in the delivery of medications which, if delivered for 24 hours, result in problems such as drug tolerance (eg nitroglycerin) or sleep disorders (eg nicotine). The drug is charged into the device (10) at a concentration such that the drug is discharged from the device after approximately 16 hours to such a degree that the delivery rate of drug to the patient decreases to such a degree that the pharmacological effect of the drug on the patient is mainly non-exterminating. . The device (10) is in the form of a laminated composite adapted to car attached to a specific area of unbroken skin or mucosal tissue. The individual layers of the device include an upper back or, "outer skin" layer (11), an anchor adhesive layer (12), a source layer (13) into which drug and / or carriers are initially deposited, a contact adhesive (14). ) which is adapted to attach to skin or mucosa, and a finishing layer (15).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93504492A | 1992-08-25 | 1992-08-25 | |
PCT/US1992/010672 WO1994004109A1 (en) | 1992-08-25 | 1992-12-10 | Printed transdermal drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
NO950725D0 NO950725D0 (en) | 1995-02-24 |
NO950725L true NO950725L (en) | 1995-04-10 |
Family
ID=25466511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO950725A NO950725L (en) | 1992-08-25 | 1995-02-24 | Pressure transdermal drug delivery device |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0656771A4 (en) |
JP (1) | JPH08502727A (en) |
KR (1) | KR950702811A (en) |
AU (1) | AU3247193A (en) |
CA (1) | CA2142871A1 (en) |
FI (1) | FI950766A (en) |
NO (1) | NO950725L (en) |
WO (1) | WO1994004109A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19649534B4 (en) | 1996-11-29 | 2004-05-06 | Lts Lohmann Therapie-Systeme Ag | Packing made of composite packaging for packaging active ingredient-containing patches |
DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
HU225734B1 (en) * | 1999-07-28 | 2007-07-30 | Zoltan Dardai | Multilayer plaster for introducing peptidaceous pharmacons in living organisms and process for producing thereof |
DE10110391A1 (en) | 2001-03-03 | 2002-09-26 | Lohmann Therapie Syst Lts | Highly flexible nicotine transdermal therapeutic system with nicotine as active ingredient |
DE10234673B4 (en) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
WO2005039685A1 (en) | 2003-10-27 | 2005-05-06 | University Of Basel | Transdermal drug delivery method and system |
JP4745747B2 (en) * | 2004-08-12 | 2011-08-10 | 日東電工株式会社 | Fentanyl-containing patch preparation |
JP4824963B2 (en) | 2004-08-12 | 2011-11-30 | 日東電工株式会社 | Patch and patch preparation |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | Biosynchronous transdermal drug delivery |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
IL177071A0 (en) * | 2005-08-01 | 2006-12-10 | Nitto Denko Corp | Method of preparing a nicotine transdermal preparation |
ES2499067T3 (en) | 2005-10-13 | 2014-09-26 | Nitto Denko Corporation | Transdermal preparation of nicotine and its production method |
JP5535497B2 (en) * | 2008-03-06 | 2014-07-02 | リンテック株式会社 | Transdermal patch |
JP5460971B2 (en) * | 2008-03-28 | 2014-04-02 | リンテック株式会社 | Transdermal patch |
RS54173B1 (en) * | 2010-12-14 | 2015-12-31 | Acino Ag | Transdermal therapeutic system for application of an agent |
CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
JP2018511355A (en) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Drug delivery method and system |
JP2018511127A (en) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Craving input and support system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5016652A (en) * | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
IL86170A (en) * | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
US4839174A (en) * | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US5064654A (en) * | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
US4908213A (en) * | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
-
1992
- 1992-12-10 WO PCT/US1992/010672 patent/WO1994004109A1/en not_active Application Discontinuation
- 1992-12-10 AU AU32471/93A patent/AU3247193A/en not_active Abandoned
- 1992-12-10 JP JP6506213A patent/JPH08502727A/en active Pending
- 1992-12-10 KR KR1019950700729A patent/KR950702811A/en not_active Application Discontinuation
- 1992-12-10 EP EP93901003A patent/EP0656771A4/en not_active Withdrawn
- 1992-12-10 CA CA002142871A patent/CA2142871A1/en not_active Abandoned
-
1995
- 1995-02-20 FI FI950766A patent/FI950766A/en not_active Application Discontinuation
- 1995-02-24 NO NO950725A patent/NO950725L/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO950725D0 (en) | 1995-02-24 |
EP0656771A4 (en) | 1996-07-31 |
WO1994004109A1 (en) | 1994-03-03 |
JPH08502727A (en) | 1996-03-26 |
AU3247193A (en) | 1994-03-15 |
KR950702811A (en) | 1995-08-23 |
FI950766A0 (en) | 1995-02-20 |
EP0656771A1 (en) | 1995-06-14 |
FI950766A (en) | 1995-03-22 |
CA2142871A1 (en) | 1994-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO950725L (en) | Pressure transdermal drug delivery device | |
US5635204A (en) | Method for transdermal induction of anesthesia, analgesia or sedation | |
US11471424B2 (en) | Biosynchronous transdermal drug delivery | |
EP0246385B1 (en) | Transcutaneous application of nicotine | |
US5603947A (en) | Method and device for providing nicotine replacement therapy transdermally/transbuccally | |
Madhav et al. | Orotransmucosal drug delivery systems: a review | |
Svedmyr | Fenoterol: A Beta2‐adrenergic Agonist for Use in Asthma; Pharmacology, Pharmacokinetics, Clinical Efficacy and Adverse Effects | |
EP1137406B2 (en) | Transdermal patch for delivering volatile liquid drugs | |
MX9603667A (en) | Drug-containing adhesive composite transdermal delivery device. | |
CA2064687A1 (en) | Method and device for administering dexmedetomidine transdermaly | |
EP1450773B1 (en) | Transdermal therapeutic system provided with improved long-term carrying comfort | |
HU221159B1 (en) | Process for preparation pharmaceutical compositions containing galanthamine for treating nicotine dependence | |
FR2718020A1 (en) | Heterofunctional mucoadhesive dosage composition. | |
US6582737B2 (en) | Pharmaceutical composition containing two active ingredients for smoking cessation | |
Stanley et al. | Novel delivery systems: oral transmucosal and intranasal transmucosal | |
EA002197B1 (en) | Transmucosal formulations of levosimendan | |
WO2003079976A3 (en) | A substance with sedative effect | |
KR20010102239A (en) | Pharmaceutical composition containing deoxypeganine for the treatment of drug dependence | |
US20070265238A1 (en) | Method for accelerating reentrainment of a circadian rhythm | |
Streisand et al. | Newer drug delivery systems | |
Cuber et al. | Role of cyclic nucleotides and calcium in the nutrient‐induced release of cholecystokinin‐like immunoreactivity in rats. | |
CN100363006C (en) | Drug addiction-stopping formulation and preparation thereof | |
Glass | Treatment of rattlesnake bites | |
Popale et al. | BUCCAL DRUG DELIVERY SYSTEM: THE CURRENT APPROACHES | |
SU1706624A1 (en) | Method for curing opiumism and morphinism |